Lindsey Roeker

Dec 18, 2023 | healio.com | Savannah Demko |Mindy Valcarcel |Lindsey Roeker

You've successfully added Hematology Oncology: Leukemia to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Fixed-duration pirtobrutinib plus venetoclax with or without rituximab was well-tolerated in relapsed or refractory CLL.